Immunotech Biopharm (HKSE:06978) OCF Margin %: 0.00% (As of Dec. 2025)


HKSE:06978 Immunotech Biopharm Ltd HKSE:06978
20 GF Score
Price HK$0.54
! 3 Warning Signs
View Full Analysis

What is Immunotech Biopharm OCF Margin %?

Immunotech Biopharm HKSE:06978 -1.82% 20 OCF Margin % is 0.00% as of Dec. 2025. GuruFocus rates HKSE:06978 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review. Among 960 Biotechnology companies, Immunotech Biopharm ranks worse than 104166.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Immunotech Biopharm's Cash Flow from Operations for the six months ended in Dec. 2025 was HK$-57.58 Mil. Immunotech Biopharm's Revenue for the six months ended in Dec. 2025 was HK$0.00 Mil. Therefore, Immunotech Biopharm's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Immunotech Biopharm's current OCF Yield % is -32.07%.

The historical rank and industry rank for Immunotech Biopharm's OCF Margin % or its related term are showing as below:


HKSE:06978's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Immunotech Biopharm OCF Margin % Related Terms

Immunotech Biopharm OCF Margin % Historical Data

* Premium members only.

The historical data trend for Immunotech Biopharm's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunotech Biopharm OCF Margin % Chart

Immunotech Biopharm Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Immunotech Biopharm Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HKSE:06978
20GF Score
Immunotech Biopharm Ltd HKSE:06978
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunotech Biopharm OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Immunotech Biopharm's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-107.48/0
= %

Immunotech Biopharm's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-57.58/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Immunotech Biopharm (HKSE:06978) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Immunotech Biopharm and its competitors. According to the industry distribution chart, Immunotech Biopharm ranks #999999 out of 960 companies in the Biotechnology industry.
Is Immunotech Biopharm's OCF Margin % too high?
Immunotech Biopharm's current OCF Margin % is 0.00%. Based on the distribution chart, Immunotech Biopharm ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Immunotech Biopharm has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Immunotech Biopharm's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immunotech Biopharm ranks #999999 out of 960 companies for OCF Margin %. This places Immunotech Biopharm in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Immunotech Biopharm and its competitors. Immunotech Biopharm's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunotech Biopharm stock overvalued right now?
Immunotech Biopharm (HKSE:06978) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Immunotech Biopharm's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Immunotech Biopharm (HKSE:06978), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immunotech Biopharm Business Description

Address No.1 Kangding Street, 8th Floor, Block 1, Guosheng Technology Park, Beijing Economic-technological Development Area, Beijing, CHN, 100176
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
20GF Score

Get the complete analysis for HKSE:06978

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.54
Price